Price analysis of ibrutinib/ibrutinib

Ibrutinib/Ibrutinib, its core component Ibrutinib, has brought new treatment hope to many blood cancer patients. This drug is mainly used to treat adult patients with blood cancers that have failed to respond to traditional therapies or have relapsed, covering a variety of conditions such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and Waldenströ macroglobulinemia.

In the treatment of MCLIbrutinib can be used alone; in the treatment of CLL, it can be used alone or in combination with drugs such as bendamustine, rituximab, otuzumab, or venetoclax to provide a more comprehensive therapeutic effect. For Waldenströ macroglobulinemia, ibrutinib has also shown potential as a treatment alone or in combination with rituximab.

In the domestic market, the original ibrutinib drug is supplied in capsule form and has been successfully included in the Class B medical insurance reimbursement catalog, but only patients who meet the indications can enjoy reimbursement benefits. Its common specifications are 140mg*90 capsules, and the price is approximately RMB 10,000. However, in overseas markets, the price of the same original drug may be as high as more than 10,000 US dollars, which is obviously more expensive.

It is worth mentioning that many overseas countries have begun to produce and sell generic drugs of ibrutinib. These generic drugs are highly consistent in ingredients with the original drugs, but are more affordable. For example, the price of generic drugs such as the Bangladeshi, Indian and Lao versions may range from just a few hundred to 1,000 yuan per box (please note that prices may fluctuate due to exchange rates). This undoubtedly provides a more economical and affordable treatment option for the majority of patients.